**Supplement 1: Quality of studies**

1. **Analytical Cross-sectional studies**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author | Were the criteria for inclusion in the sample clearly defined? | Were the study subjects and the setting described in detail? | Was the exposure measured in a valid and reliable way? | Were objective, standard criteria used for measurement of the condition? | Were confounding factors identified? | Were strategies to deal with confounding factors stated? | Were the outcomes measured in a valid and reliable way? | Was appropriate statistical analysis used? | Score percentage |
| (GMB) Armitage et al | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | 100 |
| (CMR) Kouotou et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (EGY) Hegab et al | ⮽ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | 88 |
|  (ETH) Ararsa et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (ETH) Haile et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (GHA) Birjandi et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (LBR) Collinson et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (VUT) Callum et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (ETH) Dagne et al | ⮽ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 75 |
| (ETH) Enbiale et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 75 |
| (ETH) Melese et al | ⮽ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 75 |
| (ETH) Walker et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 75 |
| (FJI) Romani et al | ⮽ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 75 |
| (IND) Satyamanasa et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 75 |
| (WSM) Taiaroa et al | ☑ | ☑ | ⮽ | ☑ | ⮽ | ☑ | ☑ | ☑ | 75 |
| (SLB) Lake et al | ☑ | ☑ | ⮽ | ☑ | ⮽ | ☑ | ☑ | ☑ | 75 |
| (SLB) Mason et al | ☑ | ☑ | ⮽ | ☑ | ⮽ | ☑ | ☑ | ☑ | 75 |
| (SLB) Osti et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 75 |
| (TLS) Korte et al | ⮽ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 75 |
| (TLS) Matthews et al | ☑ | ☑ | ⮽ | ☑ | ⮽ | ☑ | ☑ | ☑ | 75 |
| (GBR) Hewitt et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 75 |
| (ETH) Enbiale et al | ☑ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 63 |
| (ETH) Misganaw et al | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ⮽ | ☑ | 63 |
| (FJI) Romani et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ☑ | ☑ | ☑ | 63 |
| (FJI) Steer et al | ☑ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 63 |
| (GHA) Amoako et al | ⮽ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 63 |
| (IRN) Dehkordi et al | ⮽ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 63 |
| (MWI) Casas et al | ☑ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 63 |
| (NGA) Kalu et al | ☑ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 63 |
| (LKA) Gunathilaka et al | ⮽ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 63 |
| (TUR) Ural et al | ⮽ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 63 |
| (FJI) Steer et al  | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (FJI) Tsoi et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (GHA) Kaburi et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (IND) Devidas et al | ☑ | ☑ | ⮽ | ⮽ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (LAO) Wootton et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (MYS) Zayyid et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (NZL) Thornley et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (TLS) Santos et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (TLS) Tsoi et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (IND) Burman et al | ☑ | ☑ | ⮽ | ⮽ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (MYS) Yap et al | ⮽ | ☑ | ⮽ | ⮽ | ⮽ | ⮽ | ☑ | ☑ | 38 |
| (NGA) Ogunbiyi et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |
| (AUS) Kearns et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 75 |
| (AUS) Tasani et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 75 |
| (FJI) Haar et al | ☑ | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | 88 |
| (FJI) Hardy et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (IND) Behera et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (SLB) Coscione et al | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | 100 |
| (SLB) Marks et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 75 |
| (SLB) Marks et al | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | ☑ | ☑ | 88 |
| (TZA) Martin et al | ⮽ | ☑ | ⮽ | ☑ | ⮽ | ⮽ | ☑ | ☑ | 50 |

1. **Case-Control Study**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | Were the groups comparable other than the presence of disease in cases or the absence of disease in controls? | Were cases and controls matched appropriately? | Were the same criteria used for identification of cases and controls? | Was exposure measured in a standard, valid and reliable way? | Was exposure measured in the same way for cases and controls? | Were confounding factors identified?  | Were strategies to deal with confounding factors stated? | Were outcomes assessed in a standard, valid and reliable way for cases and controls? | Was the exposure period of interest long enough to be meaningful? | Was appropriate statistical analysis used? | Score Percentage |
| (ETH) Sara et al | ☑ | ⮽ | ☑ | ☑ | ☑ | ☑ | ☑ | ☑ | ⮽ | ☑ | 80 |

1. **Cohort Study**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Studies | Were the two groups similar and recruited from the same population? | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | Was the exposure measured in a valid and reliable way? | Were confounding factors identified? | Were strategies to deal with confounding factors stated? | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | Were the outcomes measured in a valid and reliable way? | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | Were strategies to address incomplete follow up utilized? | Was appropriate statistical analysis used? | Score percentage |
| (FJI) Steer et al | ☑ | ☑ | ⮽ | ⮽ | ⮽ | ⮽ | ☑ | ☑ | ☑ | ⮽ | ☑ | 55 |